Novolog Pharm-Up 1966 Ltd (NVLG) - Net Assets
Based on the latest financial reports, Novolog Pharm-Up 1966 Ltd (NVLG) has net assets worth ILA368.90 Million ILA (≈ $989.02K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA2.15 Billion ≈ $5.76 Million USD) and total liabilities (ILA1.78 Billion ≈ $4.77 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Novolog Pharm-Up 1966 Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA368.90 Million |
| % of Total Assets | 17.18% |
| Annual Growth Rate | 14.06% |
| 5-Year Change | -14.25% |
| 10-Year Change | 421.94% |
| Growth Volatility | 47.89 |
Novolog Pharm-Up 1966 Ltd - Net Assets Trend (2014–2025)
This chart illustrates how Novolog Pharm-Up 1966 Ltd's net assets have evolved over time, based on quarterly financial data. Also explore NVLG current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Novolog Pharm-Up 1966 Ltd (2014–2025)
The table below shows the annual net assets of Novolog Pharm-Up 1966 Ltd from 2014 to 2025. For live valuation and market cap data, see Novolog Pharm-Up 1966 Ltd (NVLG) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ILA368.90 Million ≈ $989.02K |
-3.46% |
| 2024-12-31 | ILA382.14 Million ≈ $1.02 Million |
-3.53% |
| 2023-12-31 | ILA396.12 Million ≈ $1.06 Million |
-14.27% |
| 2022-12-31 | ILA462.05 Million ≈ $1.24 Million |
+7.40% |
| 2021-12-31 | ILA430.23 Million ≈ $1.15 Million |
+45.51% |
| 2020-12-31 | ILA295.67 Million ≈ $792.68K |
+12.09% |
| 2019-12-31 | ILA263.78 Million ≈ $707.18K |
+159.59% |
| 2018-12-31 | ILA101.61 Million ≈ $272.42K |
+18.55% |
| 2017-12-31 | ILA85.71 Million ≈ $229.79K |
+21.27% |
| 2016-12-31 | ILA70.68 Million ≈ $189.49K |
-30.94% |
| 2015-12-31 | ILA102.34 Million ≈ $274.37K |
+17.94% |
| 2014-12-31 | ILA86.77 Million ≈ $232.63K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Novolog Pharm-Up 1966 Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ILA16.32 Million | 4.57% |
| Common Stock | ILA5.11 Million | 1.43% |
| Other Comprehensive Income | ILA-12.28 Million | -3.44% |
| Other Components | ILA347.70 Million | 97.44% |
| Total Equity | ILA356.85 Million | 100.00% |
Novolog Pharm-Up 1966 Ltd Competitors by Market Cap
The table below lists competitors of Novolog Pharm-Up 1966 Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GOLCONDA GOLD LTD
F:Y87
|
$117.81 Million |
|
Hod Assaf Industries Ltd
TA:HOD
|
$117.83 Million |
|
Iljin Power Co. Ltd
KQ:094820
|
$117.88 Million |
|
Chien Shing Harbour Service Co Ltd
TW:8367
|
$117.90 Million |
|
Kutahya Seker Fabrikasi AS
IS:KTSKR
|
$117.76 Million |
|
Silver Pegasus Acquisition Corp.
NASDAQ:SPEG
|
$117.76 Million |
|
Kc Cottrell
KO:119650
|
$117.68 Million |
|
Cantor Equity Partners, Inc. Class A Ordinary Shares
NASDAQ:CEP
|
$117.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Novolog Pharm-Up 1966 Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 368,375,000 to 356,851,000, a change of -11,524,000 (-3.1%).
- Net income of 4,115,000 contributed positively to equity growth.
- Dividend payments of 20,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 3,848,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA4.12 Million | +1.15% |
| Dividends Paid | ILA20.00 Million | -5.6% |
| Other Comprehensive Income | ILA3.85 Million | +1.08% |
| Other Changes | ILA513.00K | +0.14% |
| Total Change | ILA- | -3.13% |
Book Value vs Market Value Analysis
This analysis compares Novolog Pharm-Up 1966 Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 123.11x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 354.53x to 123.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | ILA0.24 | ILA86.00 | x |
| 2015-12-31 | ILA0.29 | ILA86.00 | x |
| 2016-12-31 | ILA0.20 | ILA86.00 | x |
| 2017-12-31 | ILA0.24 | ILA86.00 | x |
| 2018-12-31 | ILA0.29 | ILA86.00 | x |
| 2019-12-31 | ILA0.68 | ILA86.00 | x |
| 2020-12-31 | ILA0.62 | ILA86.00 | x |
| 2021-12-31 | ILA0.82 | ILA86.00 | x |
| 2022-12-31 | ILA0.85 | ILA86.00 | x |
| 2023-12-31 | ILA0.73 | ILA86.00 | x |
| 2024-12-31 | ILA0.72 | ILA86.00 | x |
| 2025-12-31 | ILA0.70 | ILA86.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Novolog Pharm-Up 1966 Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.23%
- • Asset Turnover: 0.84x
- • Equity Multiplier: 6.02x
- Recent ROE (1.15%) is below the historical average (15.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 27.72% | 3.74% | 0.48x | 15.53x | ILA15.05 Million |
| 2015 | 25.19% | 3.70% | 0.42x | 16.35x | ILA15.23 Million |
| 2016 | 41.20% | 3.94% | 0.49x | 21.55x | ILA22.05 Million |
| 2017 | 26.24% | 2.68% | 0.47x | 21.07x | ILA13.92 Million |
| 2018 | 21.51% | 2.40% | 0.53x | 17.05x | ILA11.70 Million |
| 2019 | 3.84% | 1.01% | 0.47x | 8.15x | ILA-16.24 Million |
| 2020 | 13.60% | 3.53% | 0.52x | 7.42x | ILA10.60 Million |
| 2021 | 9.97% | 3.37% | 0.55x | 5.39x | ILA-119.00K |
| 2022 | 10.90% | 3.15% | 0.62x | 5.58x | ILA3.91 Million |
| 2023 | -11.32% | -2.56% | 0.59x | 7.51x | ILA-79.11 Million |
| 2024 | 10.73% | 1.96% | 0.67x | 8.24x | ILA2.70 Million |
| 2025 | 1.15% | 0.23% | 0.84x | 6.02x | ILA-31.57 Million |
Industry Comparison
This section compares Novolog Pharm-Up 1966 Ltd's net assets metrics with peer companies in the Medical Distribution industry.
No peer company data available for comparison.
About Novolog Pharm-Up 1966 Ltd
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital. The Logistics division engages in the import and distribution of pharmaceuticals and medical products; logistics of clinical trials and related services; provision of pharmaceutical services to customers; and sterilization and validation pr… Read more